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Introduction: Decreased plasma vitamin D (VD) levels
are linked to cardiovascular damage. However, clinical
trials have not demonstrated a benefit of VD
supplements on left ventricular (LV) remodelling.
Anterior ST-elevation acute myocardial infarction
(STEMI) is the best human model to study the effect of
treatments on LV remodelling. We present a proof-of-
concept study that aims to investigate whether VD
improves LV remodelling in patients with anterior STEMI.
Methods and analysis: The VITamin D in Acute
Myocardial Infarction (VITDAMI) trial is a multicentre,
randomised, double-blind, placebo-controlled trial. 144
patients with anterior STEMI will be assigned to receive
calcifediol 0.266 mg capsules (Hidroferol SGC)/15 days
or placebo on a 2:1 basis during 12 months. Primary
objective: to evaluate the effect of calcifediol on LV
remodelling defined as an increase in LV end-diastolic
volume ≥10% (MRI). Secondary objectives: change in
LV end-diastolic and end-systolic volumes, ejection
fraction, LV mass, diastolic function, sphericity index and
size of fibrotic area; endothelial function; plasma levels of
aminoterminal fragment of B-type natriuretic peptide,
galectin-3 and monocyte chemoattractant protein-1;
levels of calcidiol (VD metabolite) and other components
of mineral metabolism (fibroblast growth factor-23 (FGF-
23), the soluble form of its receptor klotho,
parathormone and phosphate). Differences in the effect
of VD will be investigated according to the plasma levels
of FGF-23 and klotho. Treatment safety and tolerability
will be assessed. This is the first study to evaluate the
effect of VD on cardiac remodelling in patients with
STEMI.
Ethics and dissemination: This trial has been
approved by the corresponding Institutional Review Board
(IRB) and National Competent Authority (Agencia
Española de Medicamentos y Productos Sanitarios
(AEMPS)). It will be conducted in accordance with good
clinical practice (International Council for Harmonisation
of Technical Requirements for Pharmaceuticals for Human
Use - Good Clinical Practice (ICH-GCP)) requirements,
ethical principles of the Declaration of Helsinki and
national laws. The results will be submitted to indexed
medical journals and national and international meetings.
Trial registration number: NCT02548364; Pre-results.
Strengths and limitations of this study
▪ This study will assess the effect of vitamin D (VD)
supplements on the myocardium after an acute
myocardial infarction, which is probably the best
model to study left ventricular remodelling.
▪ In addition to calcidiol plasma levels, other com-
ponents of mineral metabolism such as fibro-
blast growth factor-23 and its soluble receptor,
klotho, will be taken into account.
▪ As a limitation, this study is not powered to
study if a potential benefit of VD on myocardial
remodelling translates into a clinical benefit. In
case of a positive result, a larger study would be
necessary to further investigate this issue.
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INTRODUCTION
Traditionally, changes in plasma levels of the components
of mineral metabolism (vitamin D (VD), fibroblast
growth factor-23 (FGF-23), parathyroid hormone (PTH)
and phosphate (P)) have been associated with renal
disease.1–3 When slight decreases in glomerular filtration
rate appear, the excretion of P is reduced. Compensatory
responses are then activated to maintain P homoeostasis,
including an increase in the levels of FGF-23 and a subse-
quent rise in those of PTH.1 FGF-23 promotes phospha-
turia and decreases levels of plasma VD, both by
downregulating synthesis and by increasing degradation.1
Although high P levels are associated with an increase
in cardiovascular events and mortality,2 the aforemen-
tioned adaptive mechanisms prevent an increase in
serum P levels in the early stages of chronic kidney
disease.1–3 However, these compensatory mechanisms
themselves are also related to cardiovascular damage.4 5
Thus, high FGF-23 plasma levels are independently asso-
ciated with endothelial dysfunction, arterial stiffness, ath-
erosclerosis burden, vascular calcification, left ventricular
(LV) hypertrophy, progression of renal disease, and inci-
dence of mortality and cardiovascular events in the
general population as well as in patients with coronary
artery disease, even after adjusting for renal glomerular
filtration.4–10 Similarly, increased PTH plasma levels are
related to LV hypertrophy, hypertension and increased
cardiovascular events.11–16 Finally, VD deficiency has
been associated with endothelial dysfunction, inflamma-
tion, vascular smooth muscle cell proliferation, vascular
calcification, activation of the renin–angiotensin system,
hypertension, myocardial infarction and stroke.17–22
However, low VD plasma levels are associated with vascu-
lar damage and also play an important role in the state of
the myocardium. In this regard, VD deficiency is asso-
ciated with rat LV hypertrophy and systolic dysfunction,
biatrial enlargement, metabolic changes, inflammation,
fibrosis and apoptosis.23
Of interest, abnormalities of mineral metabolism are
not restricted to patients with overt renal disease, as in
more than 50% of patients with coronary artery disease
we have observed a deficiency of VD. However, only 20%
of them had an estimated glomerular filtration rate
<60 mL/min/1.73 m2.10 Moreover, abnormalities of
mineral metabolism were evident even at glomerular fil-
tration rates >90 mL/min/1.73 m2.24 In addition, the
inverse relationship between VD levels and risk of coron-
ary heart disease has also been seen in the general
population.20 25
Despite the negative association between VD defi-
ciency and cardiovascular disease described in multiple
studies,10 20 26–35 clinical trials have failed to convin-
cingly demonstrate a benefit of VD supplements on
cardiovascular (CV) health. One such study was the
PRIMO trial, which showed no improvement in ventricu-
lar mass index or any other remodelling parameters
by administering paricalcitol, a selective activator of
VD receptors, to patients with chronic renal failure.36
However, experiments performed in vitro and in several
animal models of LV pressure overload show that VD
supplements attenuate LV hypertrophy, reduce cardiac
fibrosis and decrease the expression of collagen, fibro-
nectin and transforming growth factor-β, along with an
improvement of the systolic and diastolic function.37–40
The negative results of the PRIMO trial may have several
causes. The main cause could be that the population
selected was not ideal for the purpose of linking VD sup-
plements and ameliorated CV health. Second, hyperten-
sion leads to myocardial remodelling over the years, and
it seems difficult to modify this process in only 48 weeks
of therapy. Another potential reason is that FGF-23
plasma levels were not taken into account. Indeed, it has
recently been observed that low levels of VD were asso-
ciated with increasing mass and diameter when coexist-
ing with high levels of FGF-23.41 In accordance with this,
we have recently reported that low levels of VD were pre-
dictors of poor outcome in coronary patients with
FGF-23 plasma levels that were higher than the median
value of 70 RU/mL, but they were not effective predic-
tors if FGF-23 plasma levels were below the median.10
Other authors have shown similar data for the progres-
sion of chronic kidney disease.42 These data provide
support for the notion that, in addition to being an
independent marker of cardiovascular risk, FGF-23
plasma levels influence the effect of low VD levels.
Finally, klotho plasma levels were not taken into
account. This protein is a co-receptor for FGF-23, whose
extracellular portion can be released and act as an endo-
crine substance with multiple functions. Low levels of
klotho are related to kidney damage, as well as to vascu-
lar calcification and cardiac hypertrophy and fibrosis,
causing klotho to be considered an antiageing protein.43
Thus, it is possible that in people without reduced glom-
erular filtrate, klotho levels are normal and could inter-
fere with the hypertrophic effect of FGF-23. The fact
that VD may increase klotho levels reinforces the possi-
bility that this compound may have a protective cardio-
vascular effect.
In summary, there is substantial evidence demonstrat-
ing the negative effects of VD deficiency on the cardio-
vascular system, including the development of LV
hypertrophy. Despite the negative results of VD supple-
ments in previous clinical trials, the convincing evidence
obtained in animal models in which it is shown that VD
may protect the heart supports the need for a new clin-
ical trial designed to take into account the most recent
discoveries in the field. The VITamin D in Acute
Myocardial Infarction (VITDAMI) trial has been
designed as a proof-of-concept study to test the effect of
VD supplements in patients with anterior ST-elevation
myocardial infarction (STEMI). The reason is that a
great part of the remodelling process following a large
STEMI may be concentrated in the months following
the acute event, making these patients probably the best
human model for studying therapeutic interventions on
ventricular remodelling. Moreover, when STEMI affects
2 Tuñón J, et al. BMJ Open 2016;6:e011287. doi:10.1136/bmjopen-2016-011287
Open Access
group.bmj.com on November 10, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
the anterior wall of the LV, it tends to be larger than in
other locations, and remodelling is thus especially inten-
sive in these cases. In this regard, in the METOCARD
trial comparing early versus delayed β-blockade in
patients with anterior STEMI,44 45 the control group
showed an increase of 11.5% in mean LV end-diastolic
volume and a decrease of 22.8% in mean LV mass at
6 months, along with a minimal increase of 2.2% in the
ejection fraction. In addition, we will see if this effect
occurs only in those patients with FGF-23 above the
median or in all the study participants. Similarly, we will
assess possible differences in the effect of VD in patients
with klotho plasma levels above and below the median.
Based on the ideas developed above, it is possible that
benefits could be present only in patients with elevated
levels of FGF-23, in those with klotho levels below the
median or in both situations.
METHODS
Study aim
To compare the effect of 1-year treatment with calcife-
diol 0.266 mg (equivalent to 15 960 units) soft gelatin
capsules versus placebo on LV remodelling in patients
with anterior STEMI.
Primary hypothesis
The oral administration of one calcifediol 0.266 mg soft
gelatin capsule every 15 days to patients with anterior
STEMI will reduce the presence of LV remodelling
assessed by cardiac MRI, defined as an increase in LV
end-diastolic volume of ≥10%, at 1 year as compared
with the baseline assessment.
Secondary hypotheses
1. Patients receiving calcifediol will show, as compared
with those receiving placebo:
▸ Less increase in end-diastolic and end-systolic
volumes;
▸ More increase in ejection fraction;
▸ Less decrease in diastolic sphericity index, defined
as the ratio of long-axis to short-axis dimension of
the LV cavity at end diastole;46
▸ Less increase in the area of fibrosis;
▸ Better diastolic function;
▸ Better endothelial function;
▸ A significant reduction in plasma levels of one or
more of these biomarkers: N-terminal brain natri-
uretic peptide (NT-proBNP) and galectin-3, as
related to heart failure and adverse prognosis; and
monocyte chemoattractant protein-1 (MCP-1),
related to inflammation and acute ischaemic
events;47
▸ Higher plasma levels of calcidiol (25OH VD)
and/or klotho, and lower levels of FGF-23 and/or
PTH.
2. The results of the previous hypotheses will be more
evident or even restricted to those patients with
FGF-23>median and/or klotho<median plasma levels.
3. Since it is possible that calcidiol plasma levels are het-
erogeneous, patients will be also divided into three
groups according to the tertiles of calcidiol plasma
levels at 6 months to study if the hypotheses
described in item 1 hold for patients in the highest
versus lowest tertiles.
All analyses will be carried out comparing patients who
received calcifediol and placebo as specified in the
protocol, including those patients in whom calcifediol
was stopped due to high plasma levels. On the other
hand, patients giving up the study medication due to
other reasons will be excluded from the analysis. The
reason is that this is just a proof-of-concept study, where
we try to demonstrate for the first time in human beings
that taking VD supplements to reach normal calcidiol
levels may decrease LV remodelling after a STEMI. On
the other hand, we do not intend to show that anterior
STEMI must be treated with VD, as a large clinical trial
demonstrating reduction of clinical events would be
necessary for this purpose.
Trial population
Patients between 40 and 85 years of age admitted at the
hospital due to an anterior STEMI, who have received
primary angioplasty, are ready to be discharged and who
accept to participate and sign the informed consent are
eligible for randomisation. STEMI is defined by suggest-
ive symptoms, such as chest discomfort irradiated to the
arms or jaw, or just compatible symptoms as sweating,
nausea, vomiting or ill-defined malaise lasting more
than 20 min, in association with persistent ECG ST eleva-
tion and subsequent release of biomarkers of myocardial
necrosis with a standard curve.48 Diagnostic anterior ST
elevation in absence of LV hypertrophy or left bundle-
branch block is defined according to current guidelines
as new ST elevation at the J point in at least two contigu-
ous leads of ≥2 mm in V1–V6 in men, ≥1.5 mm in V2–
V3 in women and/or ≥1 mm in the remaining anterior
leads will be accepted.49 Exclusion criteria are listed in
box 1. Recruitment will be competitive.
Trial design
The VITDAMI trial is a randomised, multicentre,
double-blind, placebo-controlled trial.
The protocol (V.2.1, 1 July 2015) has been approved
by the corresponding Institutional Review Board (IRB)
and the Spanish Drug Agency (AEMPS). One-hundred
and forty-four patients with anterior STEMI will be
included at cardiology departments of the participating
sites in Spain that have been chosen because they have
the equipment and programmes needed to care for
patients with STEMI, along with the facility for cardiac
MRI. After signing the informed consent, they will
undergo cardiac examination by MRI and ECG, blood
extraction for plasma storage, ECG and non-invasive
endothelial function test (only in patients admitted to
Fundación Jiménez Díaz; figure 1) as soon as possible
and no later than 7 days after admission. Immediately
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after completing these tests, patients will be randomly
assigned to receive on a 2:1, double-blind basis an oral
dose of 0.266 mg of calcifediol or placebo every 15 days
(±1 day) during 1 year. In addition to study treatment,
patients will be managed according to standard clinical
practice based on European guidelines for STEMI.48
Given that heterogeneity in calcidiol plasma levels may
exist due to different baseline levels, a 2:1 instead of 1:1
randomisation has been chosen in order to allow com-
paring the outcomes across different ranges of calcidiol
levels.
Forty-five days after inclusion, blood will be extracted
to perform a safety determination of calcidiol and
calcium plasma levels, to adjust the dose of study medi-
cation according to the results. By phone contact, dose
adjustment will be communicated to the patient and the
appearance of potential adverse effects will be evaluated.
At months 3 and 9, adverse effects will be checked by
phone call. At month 6, patients will be seen by the
investigator to rule out adverse effects and to collect
empty blisters to confirm compliance with study medica-
tion, performing also a new blood extraction for study
plasma determinations. At this time, they will be pro-
vided study medication for the last 6 months of the
study. Finally, in month 12, procedures performed at
inclusion will be repeated, and the study drug will be dis-
continued. One month after the last dose, a follow-up
visit will be performed by phone contact to register any
possible adverse events, and the study will be finished.
Table 1 summarises the visit schedule.
Patient recruitment started in November 2015 and the
trial is expected to conclude in December 2017.
Randomisation and blinding
Patients will be randomly assigned to receive one calcife-
diol 0.266 mg soft gelatin capsule (Hidroferol SGC), or
one soft capsule, containing placebo, every 15 days.
Allocation ratio will be 2:1 and the randomisation
scheme will be computer-generated by the statistician at
the coordinating centre and block-balanced. Closed
envelopes with the randomisation sequence will be pre-
pared and distributed to the participating centres.
Randomisation will be performed by the study investiga-
tors. Treatment allocation will be blind for patients and
the research team. Unblinding will be allowed in case a
patient suffers a serious adverse event if the attending
medical team considers it necessary to preserve the
patient’s health.
Study medication
Hidroferol SGC will be used for this trial. This is a new
formulation containing 0.266 mg of calcifediol
(15 960 UI of VD) that improves bioavailability (22%)
with respect to the liquid calcifediol immediate release
oral formulation, due to its Self-Emulsifying Drug
Delivery Systems (SEDDS) pharmaceutical technology.
Box 1 Exclusion criteria
▸ Death or complications compromising patient survival (ie, car-
diogenic shock) during the index event;
▸ No primary angioplasty;
▸ Impossibility to perform the desirable revascularisation
(Severe stenoses (angiographic severity >70% or borderline
with a positive intracoronary adenosine test) are allowed only
in secondary vessels considered either not relevant by the
investigator because of the small vessel diameter or distal
lesion, or technically unfeasible due to vessel calcification or
tortuosity);
▸ Indication of cardiac transplant;
▸ Surgical coronary revascularisation during the index event;
▸ Revascularisation pending at the moment of discharge;
▸ Complications that extend the patient’s stay at the hospital for
more than 7 days;
▸ Absence of akinetic area in the anterior wall of the left
ventricle;
▸ Previous myocardial infarction;
▸ Valve prosthesis;
▸ Aortic stenosis with mean gradient >25 mm Hg (Doppler) and
stenosis of any other valve;
▸ Moderate-to-severe valve regurgitation;
▸ Cardiomyopathy (dilated, hypertrophic or restrictive);
▸ Severe left ventricle hypertrophy (wall thickness ≥17 mm in
men and ≥16 mm in women);
▸ Conditions limiting survival;
▸ Inflammatory or immune disease;
▸ Estimated glomerular filtration rate <40 mL/min/1.73 m2;
▸ Intolerance to vitamin D supplements;
▸ Indication or patient’s decision to take vitamin D or calcium;
▸ Therapy with drugs that can interfere with absorption, distribu-
tion, metabolism or excretion of Vitamin D:
– Antiepileptic (phenytoin, phenobarbital, primidone, other
enzymatic inducers);
– Cholestyramine, colestipol, orlistat;
– Penicillins;





▸ Disorders that can interfere with the pharmacokinetics or
pharmacodynamics of vitamin D: hepatic insufficiency, inflam-
matory bowel disease, sarcoidosis, tuberculosis or other
granulomatous disorders;
▸ Plasma calcium levels >10.5 mg/dL, history of hypercalciuria
or calcium litiasis;
▸ Contraindications for MRI: claustrophobic, pacemaker, defibril-
lators, resynchronisation devices or high probability that they
need them during the study (among them, patients with an
ejection fraction <30% at discharge);
▸ Impossibility to follow the patients;
▸ Difficult compliance of the therapy as estimated by the
investigator;
▸ Patient rejects to participate and/or does not sign the informed
consent;
▸ Pregnancy or lactation period;
▸ Patients participating in another clinical trial.
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Calcifediol and placebo capsules will be provided and
labelled by FAES FARMA S.A. Laboratories to ensure the
blindness of the study. Pharmacy departments at each
centre will receive the study medication, and will keep a
registry of the medication received, dispensed and
stored. The medication will be stored in appropriate
conditions and kept locked under restricted access. Any
non-used study medication and all the empty packages
will be stored until the end of the study and adequately
destroyed locally afterwards.
Adherence to study medication will be evaluated by
direct questions to the patient in each visit on how many
doses he/she has omitted. In addition, this information
will be checked with pharmacy registries to calculate the
final adherence percentage.
Safety issues
At 1.5 months, a safety assessment of plasma calcidiol
and calcium levels will be performed—after the intake
of the first three doses—as by this time calcidiol is
Figure 1 Flow chart of the VITDAMI trial. (1) Only at Fundación Jiménez Díaz. STEMI, ST-elevation myocardial infarction;
VITDAMI, VITamin D in Acute Myocardial Infarction.
Table 1 Visit schedule
V0 V1 V2 V2 V4 V5 V6
0 m 1.5 m 3 m 6 m 9 m 12 m 13 m
Inclusion/exclusion criteria X
Informed consent X
Clinical history X X X X X
Concomitant medication X X X
Physical exam X X X
Heart rate and blood pressure X X X
Haemogram and biochemistry X X X
Chest roentgenogram X X
ECG X X X
Calcidiol and calcium determination X
Biological samples X X X
Cardiac MRI X X
Echocardiogram X X
Endothelial function* X X
Dispense study medication/collect empty blisters X X X
Compliance check X X X X X
Adverse events X X X X X X
*Only in Fundación Jiménez Díaz (FJD).
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expected to reach its peak concentration. The study
therapy will be adjusted following these rules:
▸ Calcidiol >70 ng/mL or calcium >10.5 mg/dL:
therapy will be stopped and the patient will continue
to be followed.
▸ Calcidiol 30–70 ng/mL and calcium ≤10.5 mg/dL:
the dose of the study drug will be reduced to one
capsule every month as a maintenance dose.
▸ Calcidiol <30 ng/mL and calcium ≤10.5 mg/dL: the
dose of the study drug will be kept at one capsule
every 15 days.
Of interest, no baseline calcidiol measurement is per-
formed, as this is deemed unnecessary due to different
reasons. (1) In a previous study from our group on 704
patients with coronary artery disease,10 24 maximal calci-
diol levels were 51 ng/mL, far from the upper normal
limit of 70 ng/mL. (2) The dose chosen is well below
the tolerable upper intake level of 4000 IU/day.50 51 (3)
In the large VITAL clinical trial, in primary prevention,
a dose of 2000 IU/day VD is being used for 5 years
without assessing basal levels and performing only one
safety determination of calcidiol levels in a small sub-
group of patients.52
Criteria for study withdrawal
Patients may voluntarily leave the study at any time
without giving any reason and with no consequences for
their subsequent care. They will also be withdrawn from
the study at investigator criteria for the following
reasons: new myocardial infarction during treatment
period (as it may influence LV remodelling), lost to
follow-up, loss of the capacity to consent, safety concerns
(ie, unexpected serious adverse events), failure to fulfil
eligibility criteria and failure to collaborate or to comply
with study procedures. Irrespective of the reason for
withdrawal, efforts will be made by the investigator’s
team to perform the end of study visit and to register in
the clinical records and case report form (CRF) as




Comprehensive cardiac MRI will be carried out to study
cardiac function, LV mass, myocardial oedema and myo-
cardial fibrosis/necrosis. Scans will be performed with
1.5 T equipments at each participating centre. For assess-
ment of global and segmental left and right ventricular
function, and LV mass, balanced steady-state free preces-
sion with sensitivity encoding the fast parallel imaging
technique (True FISP) sequence will be used for cine
imaging. Images will be obtained at short axis (8 mm
slices from the apex to the base of the left ventricle),
four-chamber, two-chamber and three-chamber.
Myocardial oedema will be assessed matching the slice
position of the cine images, using a T2-weighted triple
IR turbo spin echo (STIR) sequence. For study of fibro-
sis/myocardial necrosis, a gadolinium-based contrast
agent will be intravenously administered. Delayed
enhancement imaging to assess necrotic myocardium
will be performed using IR Turbo-FLASH (3D-IR-GRE,
2D-IR-GRE and PSIR sequences).
The necrotic/fibrotic area is defined as an area with
delayed gadolinium uptake (high-intensity STIR signals)
and myocardium at risk as an area with oedema.
Salvaged myocardium is assessed as the difference
between myocardium at risk and the necrotic area.
Myocardium at risk, the necrotic size and the salvaged
myocardium will be expressed as percentage of the total
LV mass. In addition, the necrotic area will be also
expressed in grams. All the results will be given in abso-
lute numbers and normalised by body surface area. LV
end-diastolic and end-systolic volumes, as well as the ejec-
tion fraction and the LV sphericity index (maximal long
axis/short axis of LV cavity at end diastole), will be
assessed.46 Finally, microvascular obstruction, a param-
eter related to cardiac remodelling,53 will be assessed at
the initial MRI exploration. MRI studies will be analysed
blinded to treatment allocation at a central core labora-
tory located at the Centro Nacional de Investigaciones
Cardiovasculares Carlos III with the QMass system
(V.7.6). Fifteen per cent of the MRI studies will be ran-
domly chosen to perform interobserver and intraobser-
ver variability.
Doppler-ECG
This technique will be performed and interpreted at the
centre where the patient is included. Apical four-
chamber and two-chamber views as well as long-axis and
short-axis parasternal views will be used. Bidimensional
and M-mode echocardiography will be used to analyse
diastolic and systolic diameters of the LV, septal and pos-
terior wall thickness, ejection fraction (Simpson
method), segmental contractility using a 17-segment
model and registering areas of akinesia, dyskinesia and
hypokinesia. Diastolic function will be assessed by analys-
ing the deceleration time (ms), peak E and A waves
(cm/s), E/A ratio, and the isovolumetric relaxation time
(ms) by pulsed Doppler, and E′ (cm/s) and A′ (cm/s)
waves by tissue Doppler imaging.
Endothelial function test
The ENDOPAT technology will be used, measuring
changes of finger arterial pulsatile volume (reactive
hyperaemia plethysmographic biosensors). This test will
be carried out in the subgroup of patients at the
Fundación Jiménez Díaz. Given that this group will have
a small sample size, subgroup analysis will not be per-
formed and only comparisons between both groups of
therapy will be carried out.
Blood extractions and assessments
At blood withdrawal, 26 mL will be obtained, from
which 18 mL will be placed in EDTA tubes and 8 mL in
tubes without EDTA. Blood will undergo centrifugation
for 10 min at 2.500 G and the obtained plasma will be
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stored in 2 mL cryovials at −80°C. Half of these samples
will be stored at Instituto de Investigación Sanitaria
Fundación Jiménez Díaz (IIS-FJD) and the other half at
Móstoles University Hospital to limit the probabilities of
damaging the samples in case of failure of the freezer.
Nevertheless, both freezers have a CO2 release system
and telephonic alarm in cases of malfunction of the
system. The study of mineral metabolism will be per-
formed at the laboratory of renal function at
Gómez-Ulla Hospital, and the remaining determinations
will be carried out at the laboratories of biochemistry
and vascular pathology at Fundación Jiménez Díaz.
Calcidiol levels will be quantified using chemilumines-
cent immunoassay with LIAISON XLanalyser (total VD
Assay DiaSorin, Saluggia, Italy). FGF-23 will be assessed
by an ELISA that recognises epitopes in the terminal
portion carboxyl terminus of FGF-23 (Human FGF-23,
C-Term, Immutopics, San Clemente, California, USA),
klotho will be studied by ELISA (soluble α-klotho ELISA,
IBL International, Hamburg, Germany), intact PTH by
an automated chemiluminescent method of second gen-
eration (2010 platform Elecsys, Roche Diagnostics,
Mannheim, Germany) and P will be assessed by enzym-
atic method (Integra 400 analyser, Roche Diagnostics,
Mannheim, Germany). NT-proBNP levels will be deter-
mined by immunoassay (VITROS, Orthoclinical
Diagnostics, USA), high-sensitivity C reactive proteins by
immunoturbidimetric latex and determinations of lipids,
glucose and creatinine will be carried out by standard
methods (ADVIA 2400 Chemistry System, Siemens,
Germany). Plasma levels of MCP-1 and galectin-3 will be
determined in duplicate using commercially available
ELISA kits (BMS279/2, Bender MedSystems, Burlingame,
California; and DCP00, R&D Systems, Minneapolis,
Minnesota). Albumin and calcium will be assessed by
standard methods (ADVIA 2400 Chemistry System,
Siemens, Germany).
Finally, if the patient consents, the remaining plasma
samples will be stored in a registered collection
(Instituto de Salud Carlos III, C.0003386) for future
determinations of plasma levels of other molecules that
may be potentially related to the other variables
assessed, such as mineral metabolism or LV remodelling.
Trial outcomes
Main outcome: Proportion of patients who develop LV
remodelling defined as an increase of ≥10% in the end-
diastolic volume measured by cardiac MRI at the end of
the study as compared with the baseline assessment.
Secondary outcomes
▸ Per cent change in LV end-diastolic volume;
▸ Per cent change in LV end-systolic volume;
▸ Per cent change in ejection fraction;
▸ Per cent change in sphericity index;
▸ Per cent change in size of the necrotic/fibrotic area,
defined as delayed gadolinium uptake (high-intensity
STIR signals);
▸ Per cent change in LV mass;
▸ Per cent change in endothelial function;
▸ Per cent change in diastolic function as assessed by
flow and tissue Doppler;
▸ Adverse events rate and description;
▸ Compliance rate;
▸ Incidence of heart failure, death or any acute coron-
ary syndrome (STEMI or non-ST-elevation acute cor-
onary syndrome);
▸ Levels of the following biomarkers in plasma will be
measured at 6 and 12 months:
– NT-proBNP, galectin-3, MCP-1 and high sensitive-C
reactive protein;
– Calcidiol, FGF-23, PTH, P and klotho.
In addition to comparing the changes in the final
versus the baseline assessment of all the mentioned vari-
ables, we will also compare the results obtained in the
final visit between both treatment groups.
Also, assessment of main and secondary outcomes will
be performed in the following subgroup of patients:
▸ FGF-23 plasma levels above and below the median;
▸ Klotho plasma levels above and below the median;
▸ Estimated glomerular filtration rate above and below
60 mL/min/1.73 m2;
▸ Different tertiles of calcidiol plasma levels. Also, pre-
specified cut-off levels will be set 10, 15 and 20 ng/mL
plasma levels;
▸ Different degrees of microvascular obstruction at
baseline MRI;
▸ With/without thrombectomy at primary angioplasty;




As there are no published data on the effect of VD on
LV remodelling in patients with STEMI, a formal sample
size calculation based on the expected effect for the
primary end point has not been performed. From this
point of view, the trial can be considered exploratory for
the primary outcome. First, we defined as remodelling
an increase in 10% of LV end-diastolic volume, given
that according to previous studies this value is above the
observed intraobserver and interobserver variability for
this parameter in cardiac MRI.54 Then the probability
that a variation higher than 10% in the final study as
compared with the baseline is due to observational vari-
ability is very low. Then we reviewed data from the
METOCARD study,44 comparing early versus delayed
β-blockade in a similar population, and observed that
52% of patients from the group of conventional
β-blockade developed this outcome at 6 months. Given
that we expect this number to be higher at 1 year, we
believe that a reduction of 24% in the number of
patients is a reasonable target if VD really has a positive
effect. With these numbers, we estimate that 120 patients
are needed to have a power of 80% (1−β=0.8) using a
two-sided test with a level of significance α=0.05,
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assuming that the LV end-diastolic volume measured by
MRI is normally distributed.
To have 120 cases suitable for analysis, we have esti-
mated that it is necessary to include a total of 144
patients. With this sample size, considering that mortal-
ity in the first year after a STEMI may be up to 5%,55
and taking into account that we have observed 2.6% of
incidence of recurrent non-fatal myocardial infarctions
during this period in our patients (unpublished data),
we will have 11 patients not completing the trial, leaving
133 patients. In addition, we estimate that up to 10% of
these patients could give up the study for other reasons,
then leading 120 patients for analysis.
Endothelial function will be assessed only in one
centre. However, information regarding endothelial
function is available from one previous study by Tarcin
et al.56 The authors describe that flow-mediated vasodila-
tion increases significantly from 7.0±3.2% to 10.4±3.3%
after treatment with VD. Assuming that similar differ-
ences will be observed in our study, 33 participants
would be enough to have a power of 80% with a two-
sided level of significance α=0.05.
Statistical analysis
Analyses of treatment effect will be performed as per
protocol. No interim analyses will be performed, given
the short duration and the limited sample used in this
proof-of-concept study. A descriptive analysis of baseline
characteristics of patients included in both groups will
be performed, to ensure that they are comparable.
Qualitative variables will be described as absolute
numbers and percentages. Quantitative variables with
normal distribution (tested by the Kolmogorov-Smirnov
test) will be reported as mean (SD), and those that do
not follow a normal distribution will be described as
median (IQR).
To compare quantitative variables between the VD
and the placebo groups, Student’s t-test will be used in
case data are normally distributed. In case distribution is
not normal, the Mann-Whitney test will be performed.
For the comparison of baseline versus end of treatment
values, the paired t-test will be used for normally distrib-
uted data and the Wilcoxon test will be carried out if
normal distribution cannot be demonstrated. For quali-
tative variables, χ2 test will be performed.
Also, differences in the same parameters will be
assessed among the groups defined by plasma calcidiol
tertiles. For quantitative data, one-way analysis of vari-
ance (ANOVA) followed by post hoc tests will be used in
cases of normal distribution. The Kruskal-Wallis test fol-
lowed by Mann-Whitney tests will be performed if the
distribution is not normal. Qualitative analyses will be
performed by χ2 test.
Interobserver variability will be assessed by the estima-
tion of intraclass correlation coefficients. Analyses will be
considered significant when ‘p’<0.05 (two-tailed).
Analyses will be performed with the SPSS V.19.0 statis-
tical package.
ETHICS AND DISSEMINATION
Any relevant amendments to the protocol will be
adequately submitted for evaluation to the correspond-
ing institutions and properly communicated to relevant
parties after approval. Patient confidentiality will be war-
ranted according to Spanish data protection laws. In the
CRF and any other of the trial documents, patients will
be identified by a numeric code and will not contain
any personal information that could allow identification.
We have contracted liability insurance to cover the
patients from potential adverse consequences secondary
to their participation in the trial.
All patients must sign an informed consent form
before participating and keep a copy for their records.
Investigators are responsible for obtaining written
informed consent from each individual participating in
this study after adequate explanation of the aims,
methods, objectives and potential hazards of the study.
It should be made clear that refusal to participate or
withdrawal from the trial at any stage will have no conse-
quences on the patient’s subsequent care. A specific
section to consent for the storage of biological samples
is included in the informed consent form. Clinical Trial
Pharmacovigilance and Monitoring will be performed
by the Spanish Clinical Research Network (SCReN)
every 6 months, reviewing CRF and confirming that they
only include data registered at the patient’s hospital clin-
ical records. The results of the study will be submitted to
indexed medical journals and presented at national and
international meetings. The trial is registered in
ClinicalTrials.gov (NCT02548364) and the EU Clinical
Trials Register (EudraCT 2014-004512-11).
CONCLUSIONS
The VITDAMI trial is the first exploratory trial to evalu-
ate the effect of VD treatment on myocardial remodel-
ling in patients with anterior STEMI and preserved
renal function. Furthermore, it will be the first study to
analyse the influence of other components of mineral
metabolism, such as FGF-23 and klotho levels, on the
effect of VD. The results, expected by December 2017,
will most likely contribute to our understanding of the
complex role of VD and other components of mineral
metabolism in cardiovascular diseases. If the trial is suc-
cessful, a large-scale study should be performed to see if
the improvement in cardiac remodelling translates into
clinical benefits.
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